Join our daily newsletter At The Bell to receive exclusive market insights
- Cann Global (CGB) has received a shipment for its Instacann THC 5mg product
- The product is now available for patients to buy on prescription with further awareness on cannabidiol for medicinal purposes being rolled out to GPs
- CGB also began the soft launch of its plant based skincare range, Fuss Pot in Australia last month
- Additionally, its new health food brand, Grass Roots is expected to launch in quarter three of FY22
- Shares are trading 16.7 per cent lower at 0.3 cents a share
Cann Global (CGB) has received a shipment for its Instacann THC 5mg product which is now available for patients to buy on prescription.
Instacann is a tablet containing cannabidiol for medicinal use. The company is continuing to build awareness on the product and its availability to GPs.
The healthcare stock provided other company updates including the soft launch of its plant-based skincare range, Fuss Pot in Australia last month. Orders are being received online and dispatched from a warehouse in Brisbane.
Cann Global also provided an update on its new health food brand, Grass Roots which is expected to launch in quarter three of FY22. The new brand will feature the company’s existing products and some new ones being developed with a dietician.
CGB will hold its annual general meeting in January and is expected to provide shareholders with further information on its operations.
Shares were trading 16.7 per cent lower at 0.3 cents a share at 2:55 pm AEDT.
